Cancer protein 'can be disarmed'
E. Nigma
-----BEGIN PGP SIGNED MESSAGE-----
Scientists have found a way to disarm a protein thought to play a key
role in leukaemia and other cancers.
The breakthrough raises hopes of a new type of therapy that could
treat cancer and other diseases.
Previous attempts to neutralise the protein had failed, leading
experts to conclude it was effectively "undruggable".
The study, carried out by the US Dana-Farber Cancer Institute,
features in the journal Nature.
The protein is one of the body's transcription factors, which turn
genes on or off and set in motion genetic cascades that control how
cells grow and develop. They also help fuel the growth of tumours.
The transcription factor targeted in the latest study is a protein
called Notch.
The gene responsible for manufacturing the protein is often damaged
or mutated in patients with a form of blood cancer known as T-cell
acute lymphoblastic leukaemia (ALL).
" Stapled peptides promise to significantly expand the range of
what's considered 'druggable' "
Professor Greg Verdine Dana-Farber Cancer Institute
As a result the gene is switched on all the time, driving the
uncontrolled cell growth characteristic of cancer.
Similar abnormalities in Notch also underlie other cancers, including
lung, ovarian, pancreatic and gastrointestinal tumours.
Examining the structure of Notch closely, the researchers isolated a
potential weak spot in its structure.
They employed a state-of-the-art technique using chemical braces to
mould protein snippets called peptides into specific three
dimensional shapes.
These "stapled" peptides are readily absorbed by cells, and are so
tiny they can be deployed to alter gene regulation at specific sites.
After designing and testing several synthetic stapled peptides, the
researchers identified one that was able to disrupt Notch's function.
When tested in mice it was found to limit the growth of cancer cells.
" It may lead to alternative drugs and better treatments for this
kind of leukaemia and maybe other cancers "
Dr David Ish-Horowicz Cancer Research UK
Analysis showed that activity was depressed in genes both directly
and indirectly controlled by Notch.
The researchers hope the technique could also be used to target other
transcription factors with a similar structure.
Researcher Professor Greg Verdine said: "Stapled peptides promise to
significantly expand the range of what's considered 'druggable'.
"With our discovery, we've declared open season on transcription
factors and other intractable drug targets."
Dr David Ish-Horowicz, head of developmental genetics at Cancer
Research UK's London Research Institute, described the research as
"very interesting".
He said: "There is already considerable work by scientists into ways
to block Notch to try and reverse the effects of ALL, but the current
drugs have some serious side-effects.
"This study describes the design of a new chemical that blocks the
mechanism in a different way.
"The new chemical has only been tested in mice so far, and so we
don't know how it will behave in humans.
"But, long term, it may lead to alternative drugs and better
treatments for this kind of leukaemia and maybe other cancers."
Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/8353229.stm
============================
E.
-----BEGIN PGP SIGNATURE-----
Version: PGP Personal Privacy 6.5.3
Comment: E.
iQEVAwUBSvxAQ9AqdZr/mrO9AQFZzAf+K+93wVnlIYqvZvfO0KAGpAxBBmzCybra
jftqkmHitrdEVOfHJKnp5WxzmNd9LRDQ6VHHxdNGMsSKSc3WFnWUTF8G6HJ27mOu
xmM605OLknsJEtrQhADGSPNUMDzjt4D6JM0pL+lSGg6c/4D/RVLimp1RwfeXc0Pk
WQC0m3TtozBnTVi7B02bf9jTofab9Rp4/3TVoLXgHimewqOrhrK4UczsZ0F/OuFz
bUowNd2q312Qcg8nIL9rS7ahPqjBgCJ2oZxNqb7O0QRUSSlZH7EPclQJavgvQ2g5
xXi5DsX/2a6A+nlnkofd4EF+51MxcbBg0hw6WsIV0Yjnx9KR8kn0dA==
=rpc7
-----END PGP SIGNATURE-----